Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE:DRREDDY)(NYSE: RDY) reported on Thursday the availability of Albendazole Tablets, USP in the US market.
The company added the US Food and Drug Administration (USFDA) approved Albendazole Tablets, USP is a therapeutic equivalent generic version of Albenza Tablets in 200mg in bottle count sizes of two. Albenza is a trademark of Glaxosmithkline.
For the most recent 12 months ending in November 2020, the Albenza brand and generic had US sales of approximately USD27m MAT, according to IQVIA Health.
lbendazole (albendazolum) is an oral medication used for the treatment of a variety of parasitic worm infestations. It is useful for giardiasis, trichuriasis, filariasis, neurocysticercosis, hydatid disease, pinworm disease and ascariasis, among other diseases, concluded the company.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream